In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.